Cytori (CYTX) Receives 510(k) Clearance for Puregraft(R) from FDA

Cytori (NASDAQ: CYTX) has received 510(k) clearance from the U.S. FDA for the Puregraft 850 System for body contouring using a patient's own fat. The Puregraft 850 product line extension provides optimized and sterile processing of up to 850 mL of tissue, a significantly larger volume than the Puregraft 250, which received a 510(k) in January 2010. Larger tissue volumes expand the range of soft tissue procedures for which the product line may be used.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA clears Adicet Bio IND application for prostate cancer therapy
• Gap Inc. names Michael Francis as Old Navy CEO effective November
• Solstice scraps Element Solutions deal, approves $500M buyback